In the SWITCH Trials, DeVries JH et al. concluded that higher day-to-day fasting blood glucose variability is associated with an increased risk of overall symptomatic severe hypoglycemia in insulin-treated patients (5). This evidence concerns the gene INS and Hypoglycemia.